To Determine the Seroprevalance of Hepatitis B Surface Antigen (HBsAg) and ANTI-HCV Antibodies in Patients Undergoing HaemodialysisJournal: International Journal of Science and Research (IJSR) (Vol.9, No. 11)
Publication Date: 2020-11-05
Authors : Krishna Kant Sharma; Rahul Soni; Sweta Gupta;
Page : 674-676
Keywords : HBsAg; Anti-HCV; Haemodialysis;
Hepatitis B and C is globally one of the most common and severe infectious diseases that leads to significant morbidity and mortality. As such chronic kidney disease is an immune-deficient state, hence blood-borne viral infection particularly HBV and HCV are an important cause of morbidity and mortality of patients treated by haemodialysis. Patients who have undergone haemodialysis for end-stage renal failure are at a higher risk for infections. Aim of the study was to determine the seroprevalence of hepatitis B surface antigen (HBsAg) and Anti-HCV antibodies in patients undergoing Haemodialysis. Serological test for Hepatitis B& Anti-HCV was done by immuno-chromatographic HBsAg and Anti-HCV kit or by CLIA. Immunodiagnostic System. Prevalence of HCV (50.7 %) was slightly higher than that of HBsAg (49.23 %) out the positive cases (65/695) in the Hemodialysis patient. Among the 65 patients, majority i. e.75 % HBsAg and 69 % Anti-HCV reactive were those who underwent dialysis less than50 times. We concluded that HCV was more prevalent than that of HBsAg in Hemodialysis patient more studies must be conducted for further research.
Other Latest Articles
Last modified: 2021-06-28 17:16:04